Susvimo (ranibizumab 100mg/mL, Roche)1 has been registered by the Therapeutic Goods Administration (TGA) for use with the already approved Contivue ocular implant.2 The registration enables the clinical application of Roche’s Port Delivery Platform (known as Contivue with Susvimo in Australia), introducing the nation’s first continuous drug-delivery system for neovascular (wet) age-related macular degeneration (nAMD).1,2,3
While the Contivue ocular implant was listed on the Australian Register of Therapeutic Goods (ARTG) earlier this year as a medical device,* registration of Susvimo1 provides the customised ranibizumab formulation1,3 designed specifically for use within it – bringing the complete delivery platform together for Australian clinicians and patients.
Susvimo is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD) who have previously responded to at least two intravitreal anti-VEGF injections.3
Neovascular AMD affects an estimated 160,000 Australians over the age of 50 and is a leading cause of severe vision loss.4 Managing the condition requires ongoing therapy to maintain sight.4 While anti-VEGF intravitreal injections have significantly improved outcomes for patients, managing chronic retinal disease remains a lifelong commitment, and the ongoing burden of clinic travel and treatment fatigue remains a challenge for many.4
For suitable patients, the registration of Susvimo, administered through the surgically implanted Contivue, offers clinicians and patients an option designed to deliver continuous anti-VEGF release with refill-exchange procedures administered every 24 weeks (approximately 6 months).3,5-7
Dr Nic Horridge, General Manager, Roche Pharmaceuticals Australia.
Dr Nic Horridge, General Manager, Roche Pharmaceuticals Australia, said the TGA registration represents an important step in delivering tailored options for Australians living with debilitating eye conditions.
“We know that fear of vision loss is often compounded by the burden of frequent clinic visits,” said Dr Horridge. “While regular intravitreal injections remain the cornerstone of care for most patients,8 the TGA registration of Contivue with the Susvimo system expands our local portfolio, providing clinicians a specialised, continuous-release alternative to support selected patients where treatment burden is a critical factor for disease management.”1,2
Roche Australia is pursuing reimbursement to facilitate equitable and affordable access for eligible patients.
References
- Australian Register of Therapeutic Goods (ARTG) Listing. Therapeutic Goods Administration (TGA). Available at tga.gov.au [SUSVIMO ARTG ID: 510105]
- Australian Register of Therapeutic Goods (ARTG) Listing. Therapeutic Goods Administration (TGA). Available at tga.gov.au [CONTIVUE ARTG IDs: 528873, 520983, 521338, 521337]
- Susvimo product information. Prepared September 2026.
- Hunyor A, Kwan A. Everything you need to know about age-related macular degeneration. MJA InSight+ / Macular Disease Foundation Australia. Published online 2022. Available from mdfoundation.com.au/news/everything-you-need-to-know-about-amd.
- Regillo C, Berger B, Barteselli G, et al. Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024.
- Graff JM, et al. Presented at EURETINA 4–7 September 2025.
- Khanani AM, et al. Presented at EURETINA 4–7 September 2025
- Macular Disease Foundation Australia. 2022 research update: Innovation continues in macular disease treatment. Published December 2, 2022. Available at mdfoundation.com.au/news/2022-research-update.
